Labcorp Buys Myriad's Prenatal Business: What Labs and Clinics Should Do
Short answer: Labcorp agreed to buy Myriad Genetics' Prenatal Health business for $210 million in cash plus inventory, with closing expected in early 2027. Labs and clinics should treat it as a pending transaction: nothing changes today, but payer contracts, billing entities, and ordering workflows deserve review before closing.
What was announced
On October 20, 2026, Labcorp and Myriad Genetics announced a definitive agreement under which Labcorp will acquire Myriad's Prenatal Health testing business. Myriad's Form 8-K states the asset purchase agreement is dated October 19, 2026 and lists the Foresight Carrier Screen, Prequel Prenatal Screen, FirstGene 4-in-1 Prenatal Screen, and SneakPeek Early Gender Test. The price is $210 million in cash plus the value of the business's inventory at closing.
Labcorp said it expects the business to add approximately $160 million in revenue in the first year, to be slightly accretive to adjusted earnings in year one, and to reach average diagnostics segment margins by the end of year two once fully integrated. Over the last twelve months, the portfolio was used by thousands of providers and more than 600,000 patients, according to the release.
Closing conditions and timeline
The 8-K says closing requires expiration or termination of the Hart-Scott-Rodino waiting period, any required state health care law approvals and waiting periods, and receipt of certain third-party consents. It also requires no restraining order, no pending government litigation seeking to block the deal, and no material adverse effect on the business.
Either party may terminate if closing has not occurred by February 19, 2027. That date extends automatically to October 19, 2027 if only regulatory clearance conditions remain unmet. Labcorp may owe a $10.5 million termination fee in certain cases where termination results from failure to obtain certain regulatory clearances. A transition services agreement and a patent license agreement are among the ancillary agreements; the license takes effect at closing.
The filings do not say what Myriad retains. Myriad said it will comment on other related organizational changes on its Q3 earnings call on November 4, 2026. Its CEO described the sale as the outcome of a disciplined strategic review and tied it to investment in the cancer care continuum, per Fierce Biotech.
Labcorp's acquisition pattern
MDDI reports Labcorp paid $722 million upfront, plus up to $150 million in milestones tied to a prostate cancer blood test, for BioReference Health's lab testing business, and about $225 million for BioReference's oncology operations a little over a year earlier. Labcorp's CEO said the company did 12 acquisitions since 2023. At a September investor day, Labcorp's CFO said the company invested $3.7 billion in growth since 2023, including $2.3 billion in acquisitions.
For molecular and genetic labs, the pattern matters more than any single price. A national lab that keeps buying specialty franchises can bundle contracts, extend payer relationships, and push client service expectations upward across women's health, oncology, and hereditary testing.
What it means for molecular labs and RCM teams
Independent labs competing in reproductive and hereditary genetics should expect more pressure from consolidated portfolios. Labcorp framed the deal as positioning against Natera, BillionToOne, and Quest Diagnostics. Review which of your clients order across carrier screening, prenatal screening, and hereditary cancer panels, and whether your service model holds up when a competitor can offer a broader menu.
Revenue cycle teams that bill on behalf of or alongside labs involved in the transaction should map the billing chain now. Ask which legal entity will bill after closing, whether billing NPIs and tax IDs change, and how claims for dates of service near the closing date will be handled. The filings are silent on payer contracts, so anything you rely on should be confirmed in writing. Pair this with your existing controls on prior authorization for genetic testing and your denial prevention workflow, since entity or requisition changes are a common trigger for front-end errors.
What ordering clinicians and medical directors should do
Nothing needs to change on the day of announcement. The deal has not closed, and Myriad's CEO said he expects a smooth transition that keeps prenatal test access uninterrupted. Practical steps are modest: keep a record of the requisition forms and portals in use, designate one person to monitor vendor notices, and confirm how results and patient billing inquiries will be routed after closing.
Genetic counselors should note that test menus, reporting formats, and patient financial assistance programs can change after an integration even when the underlying tests continue. If your practice relies on a specific carrier screen or early screening product, ask the lab representative how and when any changes would be communicated. For broader context on how genomic screening is evolving, see our overview of newborn genomic screening in 2026.
Billing and coding checks before closing
Because the tests are laboratory developed tests, claims frequently depend on precise code selection. Teams that currently use unlisted codes should revisit their documentation habits, as covered in our guide to CPT 81479 denials. Verify that your lab information system, requisition templates, and payer enrollment records are not hard-coded to a single legal entity in ways that would break after a transfer.
A short pre-closing checklist helps: list every payer contract tied to the affected tests, note renewal dates, record current prior authorization requirements, and capture the specimen-to-claim timeline for a representative sample of cases. If the buyer changes any step, you will have a baseline to compare against.
Frequently asked questions
Which tests are included in the Labcorp-Myriad prenatal sale?
The Form 8-K lists the Foresight Carrier Screen, Prequel Prenatal Screen, FirstGene 4-in-1 Prenatal Screen, and SneakPeek Early Gender Test. The press release names the same four brands. Confirm any other Myriad catalog items directly with your representative, because the filings do not mention them.
When will the transaction close?
Labcorp's press release says early 2027. The 8-K sets a February 19, 2027 termination date that extends automatically to October 19, 2027 if only regulatory clearance conditions remain. Closing requires Hart-Scott-Rodino expiration, any required state health care approvals, and certain third-party consents.
Do payer contracts transfer automatically?
The filings do not address payer contracts. The only related reference is a closing condition for certain required third-party consents. Labs and clinics should not assume in-network status, billing NPIs, or claim routing will carry over unchanged, and should ask for written confirmation before closing.
Should ordering clinics change anything today?
Not necessarily. Myriad's CEO said he expects a smooth transition with uninterrupted access to prenatal tests, and the deal has not closed. Clinics should keep ordering as usual, but document current requisition workflows and watch for notices about portals, ordering forms, and billing entities.
Why does a prenatal deal matter to molecular labs outside prenatal?
Consolidation changes competitive and referral dynamics. Labcorp says the deal supports its specialty testing strategy and positions it against Natera, BillionToOne, and Quest Diagnostics. Independent labs in adjacent women's health and hereditary testing may see shifts in contracting leverage and client expectations.
This article is educational and intended for laboratory, clinical, and revenue cycle professionals. It is not legal, financial, coverage, or medical advice. Transaction terms are as publicly reported and may change. Confirm payer, billing, and compliance questions with qualified advisors and the parties involved.
Sources: Labcorp press release, Oct 20, 2026; Myriad Genetics Form 8-K (SEC), Oct 2026; Fierce Biotech, "Myriad Genetics to sell off Prenatal Health testing business to Labcorp"; MDDI, "Labcorp's Acquisition Spree Rolls On: Myriad's Prenatal Unit for $210M". Learn more about ScreenMyGene.